Personalis reported third-quarter revenue of $25.6 million, nearly doubling the prior-year period's $14.5 million. Clinical test revenue surged to $4.4 million from $0.4 million, driven by a 3x increase in volume to 13,157 tests and expanded Medicare coverage for immunotherapy diagnostics. Core pharma testing services contributed $17.2 million, while population sequencing generated $4.0 million. The company ended the quarter with approximately $190.6 million in cash and investments. Personalis operates in the advanced genomics sector, providing precision oncology testing solutions.
